Transcriptional Regulation by MECP2

Stable Identifier
Homo sapiens
Locations in the PathwayBrowser
SVG |   | PPTX  | SBGN
Click the image above or here to open this pathway in the Pathway Browser
MECP2 is an X chromosome gene whose loss-of-function mutations are an underlying cause of the majority of Rett syndrome cases. The MECP2 gene locus consists of four exons. Both exon 1 and exon 2 contain translation start sites. Alternative splicing of the second exon results in expression of two MECP2 transcript isoforms, MECP2_e1 (MECP2B or MECP2alpha) and MECP2_e2 (MECP2A or MECP2beta). The N-terminus of the MECP2_e1 isoform, in which exon 2 is spliced out, is encoded by exon 1. The N-terminus of the MECP2_e2 isoforms, which includes both exon 1 and exon 2, is encoded by exon 2, as the exon 2 translation start site is used. Exons 3 and 4 are present in both isoforms. The MECP2_e2 isoform was cloned first and is therefore more extensively studied. The MECP2_e1 isoform is more abundant in the brain (Mnatzakanian et al. 2004, Kriaucionis and Bird 2004, Kaddoum et al. 2013). Mecp2 isoforms show different expression patterns during mouse brain development and in adult brain regions (Dragich et al. 2007, Olson et al. 2014). While Rett syndrome mutations mainly occur in exons 3 and 4 of MECP2, thereby affecting both MECP2 isoforms (Mnatzakanian et al. 2004), some mutations occur in exon 1, affecting MECP2_e1 only. No mutations have been described in exon 2 (Gianakopoulos et al. 2012). Knockout of Mecp2_e1 isoform in mice, through a naturally occurring Rett syndrome point mutation which affects the first translation codon of MECP2_e1, recapitulates Rett-like phenotype. Knockout of Mecp2_e2 isoform in mice does not result in impairment of neurologic functions (Yasui et al. 2014). In Mecp2 null mice, transgenic expression of either Mecp2_e1 or Mecp2_e2 prevents development of Rett-like phenotype, with Mecp2_e1 rescuing more Rett-like symptoms than Mecp2_e2. This indicates that both splice variants can fulfill basic Mecp2 functions in the mouse brain (Kerr et al. 2012). Changes in gene expression upon over-expression of either MECP2_e1 or MECP2_e2 imply overlapping as well as distinct target genes (Orlic-Milacic et al. 2014).

Methyl-CpG-binding protein 2 encoded by the MECP2 gene binds to methylated CpG sequences in the DNA. The binding is not generic, however, but is affected by the underlying DNA sequence (Yoon et al. 2003). MECP2 binds to DNA containing 5 methylcytosine (5mC DNA), a DNA modification associated with transcriptional repression (Mellen et al. 2012), both in the context of CpG islands and outside of CpG islands (Chen et al. 2015). In addition, MECP2 binds to DNA containing 5 hydroxymethylcytosine (5hmC DNA), a DNA modification associated with transcriptional activation (Mellen et al. 2012). MECP2 binds to DNA as a monomer, occupying about 11 bp of the DNA. Binding of one MECP2 molecule facilitates binding of the second MECP2 molecule, and therefore clustering can occur at target sites. MECP2 binding to chromatin may be facilitated by nucleosome methylation (Ghosh et al. 2010).

MECP2 was initially proposed to act as a generic repressor of gene transcription. However, high throughput studies of MECP2-induced changes in gene expression in mouse hippocampus (Chahrour et al. 2008), and mouse and human cell lines (Orlic-Milacic et al. 2014) indicate that more genes are up-regulated than down-regulated when MECP2 is overexpressed. At least for some genes directly upregulated by MECP2, it was shown that a complex of MECP2 and CREB1 was involved in transcriptional stimulation (Chahrour et al. 2008, Chen et al. 2013).

MECP2 expression is the highest in postmitotic neurons compared to other cell types, with MECP2 being almost as abundant as core histones. Phosphorylation of MECP2 in response to neuronal activity regulates binding of MECP2 to DNA, suggesting that MECP2 may remodel chromatin in a neuronal activity-dependent manner. The resulting changes in gene expression would then modulate synaptic plasticity and behavior (reviewed by Ebert and Greenberg 2013). In human embryonic stem cell derived Rett syndrome neurons, loss of MECP2 is associated with a significant reduction in transcription of neuronally active genes, as well as the reduction in nascent protein synthesis. The reduction in nascent protein synthesis can at least in part be attributed to the decreased activity of the PI3K/AKT/mTOR signaling pathway. Neuronal morphology (reduced soma size) and the level of protein synthesis in Rett neurons can be ameliorated by treating the cells with growth factors which activate the PI3K/AKT/mTOR cascade or by inhibition of PTEN, the negative regulator of AKT activation. Mitochondrial gene expression is also downregulated in Rett neurons, which is associated with a reduced capacity of the mitochondrial electron transport chain (Ricciardi et al. 2011, Li et al. 2013). Treatment of Mecp2 null mice with IGF1 (insulin-like growth factor 1) reverses or ameliorates some Rett-like features such as locomotion, respiratory difficulties and irregular heart rate (Tropea et al. 2009).

MECP2 regulates expression of a number of ligands and receptors involved in neuronal development and function. Ligands regulated by MECP2 include BDNF (reviewed by Li and Pozzo-Miller 2014, and KhorshidAhmad et al. 2016), CRH (McGill et al. 2006, Samaco et al. 2012), SST (Somatostatin) (Chahrour et al. 2008), and DLL1 (Li et al. 2014). MECP2 also regulates transcription of genes involved in the synthesis of the neurotransmitter GABA – GAD1 (Chao et al. 2010) and GAD2 (Chao et al. 2010, He et al. 2014). MECP2 may be involved in direct stimulation of transcription from the GLUD1 gene promoter, encoding mitochondrial glutamate dehydrogenase 1, which may be involved in the turnover of the neurotransmitter glutamate (Livide et al. 2015). Receptors regulated by MECP2 include glutamate receptor GRIA2 (Qiu et al. 2012), NMDA receptor subunits GRIN2A (Durand et al. 2012) and GRIN2B (Lee et al. 2008), opioid receptors OPRK1 (Chahrour et al. 2008) and OPRM1 (Hwang et al. 2009, Hwang et al. 2010, Samaco et al. 2012), GPRIN1 (Chahrour et al. 2008), MET (Plummer et al. 2013), NOTCH1 (Li et al. 2014). Channels/transporters regulated by MECP2 include TRPC3 (Li et al. 2012) and SLC2A3 (Chen et al. 2013). MECP2 regulates transcription of FKBP5, involved in trafficking of glucocorticoid receptors (Nuber et al. 2005, Urdinguio et al. 2008). MECP2 is implicated in regulation of expression of SEMA3F (semaphorin 3F) in mouse olfactory neurons (Degano et al. 2009). In zebrafish, Mecp2 is implicated in sensory axon guidance by direct stimulation of transcription of Sema5b and Robo2 (Leong et al. 2015). MECP2 may indirectly regulate signaling by neuronal receptor tyrosine kinases by regulating transcription of protein tyrosine phosphatases, PTPN1 (Krishnan et al. 2015) and PTPN4 (Williamson et al. 2015).

MECP2 regulates transcription of several transcription factors involved in functioning of the nervous system, such as CREB1, MEF2C, RBFOX1 (Chahrour et al. 2008) and PPARG (Mann et al. 2010, Joss-Moore et al. 2011).

MECP2 associates with transcription and chromatin remodeling factors, such as CREB1 (Chahrour et al. 2008, Chen et al. 2013), the HDAC1/2-containing SIN3A co-repressor complex (Nan et al. 1998), and the NCoR/SMRT complex (Lyst et al. 2013, Ebert et al. 2013). There are contradictory reports on the interaction of MECP2 with the SWI/SNF chromatin-remodeling complex (Harikrishnan et al. 2005, Hu et al. 2006). Interaction of MECP2 with the DNA methyltransferase DNMT1 has been reported, with a concomitant increase in enzymatic activity of DNMT1 (Kimura and Shiota 2003).

In addition to DNA binding-dependent regulation of gene expression by MECP2, MECP2 may influence gene expression by interaction with components of the DROSHA microprocessor complex and the consequent change in the levels of mature microRNAs (Cheng et al. 2014, Tsujimura et al. 2015).

Increased MECP2 promoter methylation is observed in both male and female autism patients (Nagarajan et al. 2008). Regulatory elements that undergo methylation are found in the promoter and the first intron of MECP2 and their methylation was shown to regulate Mecp2 expression in mice (Liyanage et al. 2013). Mouse Mecp2 promoter methylation was shown to be affected by stress (Franklin et al. 2010).

The Rett-like phenotype of Mecp2 null mice is reversible (Guy et al. 2007), but appropriate levels of Mecp2 expression need to be achieved (Alvarez-Saavedra et al. 2007). When Mecp2 expression is restored in astrocytes of Mecp2 null mice, amelioration of Rett symptoms occurs, involving non-cell-autonomous positive effect on mutant neurons and increasing level of the excitatory glutamate transporter VGLUT1 (Lioy et al. 2011). Microglia derived from Mecp2 null mice releases higher than normal levels of glutamate, which has toxic effect on neurons. Increased glutamate secretion may be due to increased levels of glutaminase (Gls), involved in glutamate synthesis, and increased levels of connexin-32 (Gjb1), involved in glutamate release, in Mecp2 null microglia (Maezawa and Jin 2010). Targeted deletion of Mecp2 from Sim1-expressing neurons of the mouse hypothalamus recapitulates some Rett syndrome-like features and highlights the role of Mecp2 in feeding behavior and response to stress (Fyffe et al. 2008).

Mecp2 overexpression, similar to MECP2 duplication syndrome, causes neurologic phenotype similar to Rett (Collins et al. 2004, Luikenhuis et al. 2004, Van Esch et al. 2005, Alvarez-Saavedra 2007, Van Esch et al. 2012). The phenotype of the mouse model of the MECP2 duplication syndrome in adult mice is reversible when Mecp2 expression levels are corrected (Sztainberg et al. 2015).

Literature References
PubMed ID Title Journal Year
24916645 GluD1 is a common altered player in neuronal differentiation from both MECP2-mutated and CDKL5-mutated iPS cells

De Falco, G, Amabile, S, Mencarelli, MA, Renieri, A, Ariani, F, Livide, G, Amenduni, M, Lo Rizzo, C, Ulivieri, C, Yasui, D, Hell, JW, Patriarchi, T, Meloni, I, Mari, F, Calcagno, E

Eur. J. Hum. Genet. 2015
23260135 MeCP2 binds to 5hmC enriched within active genes and accessible chromatin in the nervous system

Dewell, S, Heintz, N, Mellén, M, Kriaucionis, S, Ayata, P

Cell 2012
23770565 Rett syndrome mutations abolish the interaction of MeCP2 with the NCoR/SMRT co-repressor

de Lima Alves, F, Kastan, NR, Guy, J, Greenberg, ME, Ekiert, R, Bird, A, Selfridge, J, Nowak, J, Ebert, DH, Robinson, ND, Merusi, C, Lyst, MJ, Rappsilber, J

Nat. Neurosci. 2013
25424712 Deletion of protein tyrosine phosphatase, non-receptor type 4 (PTPN4) in twins with a Rett syndrome-like phenotype

Pelka, GJ, Ellaway, CJ, Williamson, SL, Tam, PPL, Peters, GB, Christodoulou, J

Eur. J. Hum. Genet. 2015
19843474 MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis

Chu, DC, Oakley, F, Maxwell, A, Tsukamoto, H, Zhu, NL, Mann, J, Mann, DA

Gastroenterology 2010
19208815 Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice

Wilson, NR, Beard, C, Fu, DD, Giacometti, E, Jaenisch, R, Tropea, D, Sur, M, McCurry, C, Flannery, R

Proc. Natl. Acad. Sci. U.S.A. 2009
21829232 Transgenic complementation of MeCP2 deficiency: phenotypic rescue of Mecp2-null mice by isoform-specific transgenes

Abrams, A, Saez, M, Kerr, B, Soto C, J, Walz, K, Young, JI

Eur. J. Hum. Genet. 2012
16002417 Up-regulation of glucocorticoid-regulated genes in a mouse model of Rett syndrome

Guy, J, Nuber, UA, Roloff, TC, Bird, A, Lipkowitz, B, Selfridge, J, Ropers, HH, Holmes, MC, Steinhoff, C, Schulz, R, Kriaucionis, S

Hum. Mol. Genet. 2005
18989361 Mecp2-null mice provide new neuronal targets for Rett syndrome

Diaz-Uriarte, R, Fernandez, AF, Lopez-Serra, L, Lopez-Nieva, P, Urdinguio, RG, Esteller, M, Alaminos, M

PLoS ONE 2008
24699272 Over-expression of either MECP2_e1 or MECP2_e2 in neuronally differentiated cells results in different patterns of gene expression

Vincent, JB, Mahmood, H, Orlic-Milacic, M, Gianakopoulos, PJ, Kaufman, L, Mikhailov, A, Minassian, BA, Ellis, J, Cheung, AY

PLoS ONE 2014
21212100 Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model

Giustetto, M, Ricciardi, S, Landsberger, N, Boggio, EM, Pizzorusso, T, Forlani, G, Morello, N, Grosso, S, Biffo, S, Stefanelli, G, Calcagno, E, Lonetti, G, Broccoli, V

Hum. Mol. Genet. 2011
26942018 Developmental Dynamics of Rett Syndrome

Banerjee, A, Feldman, D, Sur, M

Neural Plast. 2016
26344767 miR-199a Links MeCP2 with mTOR Signaling and Its Dysregulation Leads to Rett Syndrome Phenotypes

Nakahata, Y, Itoh, M, Irie, K, Takamori, S, Nakashima, K, Egashira, Y, Uesaka, M, Imamura, T, Tsujimura, K, Nakashima, H, Fukao, Y, Yamashita, Y, Fujiwara, M, Abe, T

Cell Rep 2015
24352790 Mice with an isoform-ablating Mecp2 exon 1 mutation recapitulate the neurologic deficits of Rett syndrome

Gavino, BJ, Vincent, JB, Hu, DJ, Crary, FK, Aflatooni, JO, Carolyn Schanen, N, LaSalle, JM, Olson, CO, Gonzales, ML, Yasui, DH, Rastegar, M, Golub, MS

Hum. Mol. Genet. 2014
15034579 A previously unidentified MECP2 open reading frame defines a new protein isoform relevant to Rett syndrome

Friez, MJ, Vincent, JB, Schanen, NC, Alfred, SE, Scherer, SW, Jones, JR, Munteanu, I, MacLeod, PJ, Lohi, H, Yamada, T, Mnatzakanian, GN, Minassian, BA

Nat. Genet. 2004
24636259 MeCP2 suppresses nuclear microRNA processing and dendritic growth by regulating the DGCR8/Drosha complex

Xu, W, Zhou, WH, Wang, Z, Liao, Q, Qiu, Z, Zhu, Y, Cheng, TL

Dev. Cell 2014
17278130 Differential distribution of the MeCP2 splice variants in the postnatal mouse brain

Schanen, NC, Dragich, JM, Kim, YH, Arnold, AP

J. Comp. Neurol. 2007
21716289 A role for glia in the progression of Rett's syndrome

Kirchhoff, F, Garg, SK, Mandel, G, Kaspar, BK, Bissonnette, JM, Lioy, DT, Foust, KD, Raber, J, Hirrlinger, PG, Monaghan, CE, Ballas, N

Nature 2011
15351775 Mild overexpression of MeCP2 causes a progressive neurological disorder in mice

Armstrong, DL, Collins, AL, Noebels, JL, David Sweatt, J, Zoghbi, HY, Levenson, JM, Richman, R, Vilaythong, AP

Hum. Mol. Genet. 2004
16080119 Duplication of the MECP2 region is a frequent cause of severe mental retardation and progressive neurological symptoms in males

Marynen, P, Raynaud, M, Bienvenu, T, Jensen, LR, Bauters, M, Lugtenberg, D, Moraine, C, Gecz, J, Ignatius, J, Froyen, G, Van Esch, H, Fryns, JP, Hollanders, K, Jansen, M

Am. J. Hum. Genet. 2005
12473678 Methyl-CpG-binding protein, MeCP2, is a target molecule for maintenance DNA methyltransferase, Dnmt1

Kimura, H, Shiota, K

J. Biol. Chem. 2003
24594659 Brain region-specific expression of MeCP2 isoforms correlates with DNA methylation within Mecp2 regulatory elements

Zachariah, RM, Ezeonwuka, CD, Olson, CO, Liyanage, VR, Rastegar, M

PLoS ONE 2014
24555100 Isoform-specific anti-MeCP2 antibodies confirm that expression of the e1 isoform strongly predominates in the brain

Kaddoum, L, Panayotis, N, Mazarguil, H, Joly, E, Giglia-Mari, G, Roux, JC

F1000Res 2013
20392956 Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate

Maezawa, I, Jin, LW

J. Neurosci. 2010
22231481 Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome

Mandel-Brehm, C, Samaco, RC, Zoghbi, HY, McGill, BE, Shaw, CA, McGraw, CM

Nat. Genet. 2012
25297674 Conditional deletion of Mecp2 in parvalbumin-expressing GABAergic cells results in the absence of critical period plasticity

Chen, XJ, Li, YD, Zhang, XH, Shu, YS, He, LJ, Liu, N, Qiu, ZL, Cheng, TL

Nat Commun 2014
15069197 Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice

Giacometti, E, Jaenisch, R, Beard, CF, Luikenhuis, S

Proc. Natl. Acad. Sci. U.S.A. 2004
25579386 Transcriptional Regulation of Brain-Derived Neurotrophic Factor (BDNF) by Methyl CpG Binding Protein 2 (MeCP2): a Novel Mechanism for Re-Myelination and/or Myelin Repair Involved in the Treatment of Multiple Sclerosis (MS)

Gangadaran, S, Lakowski, TM, KhorshidAhmad, T, Cortes, C, Namaka, M, Acosta, C

Mol. Neurobiol. 2016
17289941 Reversal of neurological defects in a mouse model of Rett syndrome

Cobb, S, Guy, J, Gan, J, Bird, A, Selfridge, J

Science 2007
21068835 Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes

Neul, JL, Chahrour, M, Xue, M, Samaco, RC, Noebels, JL, Zoghbi, HY, Rubenstein, JL, Chen, H, Lu, HC, Yoo, J, Ekker, M, Heintz, N, Rosenmund, C, Gong, S, Chao, HT

Nature 2010
22679399 MECP2 Duplication Syndrome

Van Esch, H

Mol Syndromol 2012
19132145 MECP2 promoter methylation and X chromosome inactivation in autism

Patzel, KA, Hansen, RL, Jiang, R, Van de Water, J, Swanberg, SE, Robinson, WP, LaSalle, JM, Pessah, IN, Hertz-Picciotto, I, Martin, M, Nagarajan, RP, Yasui, DH

Autism Res 2008
25870282 MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome

Chen, K, Li, W, Zoghbi, HY, Lavery, LA, Chen, L, Shaw, CA, Baker, SA

Proc. Natl. Acad. Sci. U.S.A. 2015
20385708 Up-regulation of the mu-opioid receptor gene is mediated through chromatin remodeling and transcriptional factors in differentiated neuronal cells

Loh, HH, Wei, LN, Kim, DK, Law, PY, Kim, CS, Hwang, CK

Mol. Pharmacol. 2010
21425435 IUGR differentially alters MeCP2 expression and H3K9Me3 of the PPARγ gene in male and female rat lungs during alveolarization

McKnight, RA, Lane, RH, Callaway, CW, Ogata, EM, Albertine, KH, Sainz, AJ, Joss-Moore, LA, Yu, X, Wang, Y

Birth Defects Res. Part A Clin. Mol. Teratol. 2011
23493374 Creb1-Mecp2-(m)CpG complex transactivates postnatal murine neuronal glucose transporter isoform 3 expression

Thamotharan, S, Chen, Y, Devaskar, SU, Shin, BC

Endocrinology 2013
23325215 Activity-dependent neuronal signalling and autism spectrum disorder

Greenberg, ME, Ebert, DH

Nature 2013
24150225 Transcriptional regulation of the MET receptor tyrosine kinase gene by MeCP2 and sex-specific expression in autism and Rett syndrome

Bergman, MY, Evgrafov, OV, Plummer, JT, Aldinger, KA, Friez, M, Haiman, CA, Levitt, P

Transl Psychiatry 2013
26733807 Methyl-CpG Binding Protein 2 (Mecp2) Regulates Sensory Function Through Sema5b and Robo2

Lim, ZH, Leong, WY, Goh, EL, Pietri, T, Korzh, V

Front Cell Neurosci 2015
26605526 Reversal of phenotypes in MECP2 duplication mice using genetic rescue or antisense oligonucleotides

Sztainberg, Y, Tang, B, Zoghbi, HY, Liu, Z, Rigo, F, Wu, Z, Wan, YW, Swann, JW, Hao, S, Tang, J, Chen, HM

Nature 2015
16940996 Testing for association between MeCP2 and the brahma-associated SWI/SNF chromatin-remodeling complex

Bird, A, Nan, X, Wang, W, Hu, K

Nat. Genet. 2006
15696166 Brahma links the SWI/SNF chromatin-remodeling complex with MeCP2-dependent transcriptional silencing

Pal, S, Jones, PL, Bassal, S, Wang, L, Brasacchio, D, Harikrishnan, KN, El-Osta, A, Sif, S, Baker, EK, Craig, JM, Chow, MZ

Nat. Genet. 2005
17108082 Enhanced anxiety and stress-induced corticosterone release are associated with increased Crh expression in a mouse model of Rett syndrome

Carson, JP, Bundle, SF, Zoghbi, HY, McGill, BE, Yaylaoglu, MB, Thaller, C

Proc. Natl. Acad. Sci. U.S.A. 2006
24238559 Decitabine alters the expression of Mecp2 isoforms via dynamic DNA methylation at the Mecp2 regulatory elements in neural stem cells

Zachariah, RM, Liyanage, VR, Rastegar, M

Mol Autism 2013
20673872 Epigenetic transmission of the impact of early stress across generations

Linder, N, Russig, H, Vizi, S, Weiss, IC, Michalon, A, Franklin, TB, Gräff, J, Mansuy, IM

Biol. Psychiatry 2010
19225110 Phosphorylation of MeCP2 at Serine 80 regulates its chromatin association and neurological function

Sun, YE, Klose, RJ, Wu, H, Jaenisch, R, Tao, J, Sherman, NE, Martinowich, K, Schanen, C, Wang, W, Chang, Q, Hu, K

Proc. Natl. Acad. Sci. U.S.A. 2009
14527417 N-CoR mediates DNA methylation-dependent repression through a methyl CpG binding protein Kaiso

Yoon, HG, Reynolds, AB, Chan, DW, Qin, J, Wong, J

Mol. Cell 2003
22262897 The Rett syndrome protein MeCP2 regulates synaptic scaling

Ghosh, A, Qiu, Z, Zhang, Y, Liu, XY, Lieberman, DN, Sylwestrak, EL

J. Neurosci. 2012
23259945 NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2

Patrizi, A, Quast, KB, Hensch, TK, Pavlyuk, R, Fagiolini, M, Carninci, P, Saxena, A, Durand, S, Hachigian, L

Neuron 2012
15034150 The major form of MeCP2 has a novel N-terminus generated by alternative splicing

Bird, A, Kriaucionis, S

Nucleic Acids Res. 2004
9620804 Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex

Ng, HH, Nan, X, Bird, A, Turner, BM, Eisenman, RN, Laherty, CD, Johnson, CA

Nature 1998
23597512 BDNF deregulation in Rett syndrome

Pozzo-Miller, L, Li, W

Neuropharmacology 2014
18511691 MeCP2, a key contributor to neurological disease, activates and represses transcription

Qin, J, Jung, SY, Wong, ST, Zoghbi, HY, Shaw, C, Chahrour, M, Zhou, X

Science 2008
25420914 Cell cycle-linked MeCP2 phosphorylation modulates adult neurogenesis involving the Notch signalling pathway

Zhong, X, Jin, P, Chau, KF, Masliah, J, Kong, G, Chi, J, Santistevan, NJ, Kadakia, M, Zhang, J, Guo, W, Li, H, Li, X, Chang, Q, Zhao, X

Nat Commun 2014
24094325 Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons

Li, Y, Gao, Q, Muffat, J, Kwok, SM, Cheng, AW, Sur, M, Mitalipova, M, Orlando, DA, Bateup, HS, Young, RA, Hockemeyer, D, Wang, H, Lewis, CA, Lovén, J, Jaenisch, R, Vander Heiden, MG, Feldman, DA

Cell Stem Cell 2013
19628041 MeCP2 deficiency disrupts axonal guidance, fasciculation, and targeting by altering Semaphorin 3F function

Pasterkamp, RJ, Ronnett, GV, Degano, AL

Mol. Cell. Neurosci. 2009
22213695 Mutations in MECP2 exon 1 in classical Rett patients disrupt MECP2_e1 transcription, but not transcription of MECP2_e2

Vincent, JB, Windpassinger, C, Orlic-Milacic, M, Kroisel, PM, White, SJ, Gianakopoulos, PJ, Saunders, CJ, Pencea, N, Chow, EW, Mittal, K, Minassian, BA, Zhang, Y

Am. J. Med. Genet. B Neuropsychiatr. Genet. 2012
19602036 Epigenetic programming of mu-opioid receptor gene in mouse brain is regulated by MeCP2 and Brg1 chromatin remodelling factor

Choi, HS, Loh, HH, Song, KY, Wei, LN, Guo, XH, Law, PY, Kim, CS, Hwang, CK

J. Cell. Mol. Med. 2009
26214522 PTP1B inhibition suggests a therapeutic strategy for Rett syndrome

Connors, CR, Krishnan, K, Shea, SD, Krishnan, N, Tonks, NK, Van Aelst, L, Choy, MS, Peti, W, Page, R

J. Clin. Invest. 2015
23027959 Activity-dependent BDNF release and TRPC signaling is impaired in hippocampal neurons of Mecp2 mutant mice

Pozzo-Miller, L, Larimore, J, Li, W, Calfa, G

Proc. Natl. Acad. Sci. U.S.A. 2012
23770587 Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR

Kastan, NR, Greenberg, ME, Ekiert, R, Bird, AP, Lyst, MJ, Hu, LS, Gabel, HW, Cohen, S, Navarro, AJ, Ebert, DH, Robinson, ND

Nature 2013
Event Information
Orthologous Events
Cite Us!